#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haemolytic uraemic syndrome Anal squamous cell carcinoma Small cell lung cancer extensive stage Ichthyosis Chondrosarcoma Neurofibromatosis Infective uveitis Retinal artery occlusion Neurodermatitis Von Hippel-Lindau disease Thrombotic microangiopathy Gastrooesophageal cancer Obesity Complex regional pain syndrome Gastrointestinal stromal tumour More trials…

    Learn about Rare Diseases

    Haemophilia B with anti factor IX – Basic Information Malignant fibrous histiocytoma – Life with Disease Myelodysplastic syndrome – Diagnostics Sjogren’s syndrome – Life with Disease Factor VIII deficiency – Life with Disease Epidermolysis bullosa – Treatment Familial amyotrophic lateral sclerosis – Trials in Disease Rhabdomyosarcoma – Life with Disease Osteosarcoma metastatic – Trials in Disease Glomerulonephritis rapidly progressive – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Forimtamig Magnesium Citrate Hydrochlorothiazide ICOTROKINRA Atacicept Meglumine Gadoterate Rosuvastatin IBUZATRELVIR Lasn01 Anthoxanthum Odoratum Tasimelteon Ucp2 PIROXICAM Elafibranor Jk06 Ck-0045 Certolizumab Pegol ZOLPIDEM TARTRATE Misoprostol Pbf-999 More therapies…

    Learn about Your Condition

    Binge eating Chronic hepatitis C Microscopic polyangiitis Hydrocephalus Graves' disease Mitral valve incompetence Menopause Bile acid synthesis disorder Gaucher's disease type I Tinnitus HER2 protein overexpression Placenta praevia Chondrosarcoma metastatic Ovarian cancer stage III Aortic valve stenosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    • Eczema
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Czechia France Germany Poland Spain

  • A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

    Recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia Germany Hungary Poland

  • A Study of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis Who Did Not Respond Well Enough to Dupilumab Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Dupilumab
    • Upadacitinib
    Italy Romania Spain

  • Testing two moisturizing creams with urea, propylene glycol, and propylene glycol alone for preventing flare-ups in patients with atopic dermatitis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Propylene Glycol
    • Urea
    Norway Sweden

  • Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    Germany Hungary Poland Spain

  • Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

    Recruiting

    2 1
    Investigated Drugs:
    • Apg777
    Czechia France Germany Hungary Poland Spain
1 2 3 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!